Application of spectral decomposition analysis to in vivo quantification of aluminum by neutron activation analysis

Applied Radiation and Isotopes

Volumn 61, Issue 6, 2004, Pages 1353-1360

  Comsa, D C ^a   Prestwich, W V ^a   McNeill, F E ^a   Byun, S H ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Aluminum; In vivo detection; Neutron activation; Spectral decomposition analysis

Indexed keywords

ACCELERATION; ALGORITHMS; ALUMINUM; DATA ACQUISITION; DATA REDUCTION; DECOMPOSITION; DISEASES; NEUTRON ACTIVATION ANALYSIS; RADIATION EFFECTS; SENSITIVITY ANALYSIS; TOXICITY;

BONE DISEASES; MINIMUM DETECTABLE LIMIT (MDL); SPECTRAL DECOMPOSITION; VIVO PROCEDURE;

ISOTOPES;

ALUMINUM;

ACCURACY; ALGORITHM; ARTICLE; DATA ANALYSIS; DECOMPOSITION; FEASIBILITY STUDY; IN VIVO STUDY; NEUTRON ACTIVATION ANALYSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIATION DOSE; SPECTROSCOPY; TECHNIQUE;

ALGORITHMS; ALUMINUM; BODY BURDEN; COMPUTER SIMULATION; FEASIBILITY STUDIES; HUMANS; MODELS, BIOLOGICAL; NEUTRON ACTIVATION ANALYSIS; NUMERICAL ANALYSIS, COMPUTER-ASSISTED; RISK ASSESSMENT; RISK FACTORS;

EID: 4544242409     PISSN: 09698043     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.apradiso.2004.03.062     Document Type: Article

References (25)

1. Arnold, M.L., 2000. Development of an accelerator based system for in vivo neutron activation analysis measurements of manganese in humans. Ph.D. Thesis, McMaster University.
2. Arnold M.L., McNeill F.E., Stronach I.M., Pejovic-Milic A., Chettle D.R., Waker A. An accelerator based system for in vivo neutron activation analysis measurements of manganese in human hand bones. Med. Phys. 29(11):2002;2718-2724
3. Aslam, Prestwich, W.V., McNeill, F.E., Waker, A.J. Estimation of dose equivalents to patients undergoing hand irradiation at the facility developed for accelerator-based in-vivo neutron activation measurements in human hand bones. Med. Phys., in press.
4. Aslam, Prestwich, W.V., McNeill, F.E., Waker, A.J., 2001. Spectrometry and dosimetry for low energy accelerator based in vivo measurements. Annual Report McMaster Accelerator Laboratory, McMaster University, Hamilton, ON, Canada.
5. Aslam, Prestwich W.V., McNeill F.E., Waker A.J. Investigating the TEPC radiation quality factor response for low energy accelerator based clinical applications. Radiat. Prot. Dosim. 103(4):2003;311-322
6. ATSDR (Agency for Toxicological Substances and Disease Registry). Toxicological profile for aluminum, 1999. US Department of Health and Human Services, Public Health Service, visit http://www.atsdr.cdc.gov/toxprofiles/ tp22.html.
7. Cohn S.H. The present state of in vivo neutron activation analysis in clinical diagnosis and therapy. Energy Rev. 18(3):1980;599-660
8. Connor M.O., Garrett P., Dockery M., Donohoe J.F., Doyle G.D., Carmody M., Dervan P.A. Aluminum-related bone disease. Correlation between symptoms, osteoid volume, and aluminum staining. Am. J. Clin. Pathol. 86(2):1986;168-174
9. 3 with citrate or polyphenolic acids on tissue retention and distribution of aluminum in rats. Biol. Trace Elem. Res. 76:2000;245-256
10. Ellis H.A., Mawhinney W.H. Aluminum induced osteomalacia. J. Clin. Pathol. 35:1982;792-793
11. Ellis K.J. Human body composition. in vivo methods Physiol. Rev. 80(2):2000;649-680
12. Ellis, K.J., Kelleher, S.P., 1987. In vivo bone aluminium measurements in patients with renal disease. In: Ellis, K.J., Yasumura, S., Morgan, W.D. (Eds.), Vivo Body Composition Studies, London.
13. Faugere M.C., Malluche H.H. Stainable aluminum, and not aluminum content, reflects bone histology in dialyzed patients. Kidney Int. 30(5):1986;717-722
14. Ganrot P.O. Metabolism and possible health effects of aluminum. Environ. Health Perspect. 65:1986;363-441
15. Green S.R., Chettle D.R. A feasibility study of the in vivo measurement of aluminium in peripheral bone. Phys. Med. Biol. 31:1992;2387-2396
16. ICRP 23, 1975. Report of the task group on Reference Man. Pergamon Press, Oxford.
17. Kawahara M., Kato M., Kuroda Y. Effects of aluminum on the neurotoxicity of primary cultured neurons and on the aggregation of beta-amyloid protein. Brain Res. Bull. 55(2):2001;211-217
18. Maloney N.A., Ozt S.M., Alfrey A.C. Histological quantitation of aluminum in iliac bone from patients with renal failure. J. Lab. Clin. Med. 99:1982;206-216
19. Morgan W.D., McNeill E.A., Wyatt R.M., Ryde S.I.S., Evans C.J., Dutton J., Sivyer A., Williams A.J. Development of a technique to measure bone aluminium in vivo using a Cf-252 source. Yasumun S., Harrison J.G., McNeil K.J., Woodhead A.D., Dilmanian F.A. Vivo Body Composition Studies: Recent Advances. 1990;Plenum, New York
20. O'Meara J.M., Borjesson J., Chettle D.R. Improving the in vivo X-ray fluorescence (XRF) measurement of renal mercury. Appl. Radiat. Isot. 53(4-5):2000;639-646
21. Palerme S., Chettle D.R., Kennett T.J., Prestwich W.V., Webber C.E. Pilot studies for in vivo bone aluminum measurements. Basic Life Sci. 60:1993;303-306
22. Pejovic-Milic A., Arnold M.L., McNeill F.E., Chettle D.R. Monte carlo design study for in vivo bone aluminum measurement using a low energy accelerator beam. Appl. Radiat. Isot. 53(4-5):2000;657-664
23. Pejovic-Milic A., McNeill F.E., Prestwich W.V., Waker A.J., Chettle D.R. Development of an accelerator based determination of aluminum burden in peripheral bone by neutron activation analysis. Appl. Radiat. Isot. 49(5-6):1998;717-719
24. Venturini-Soriano M., Berthon G. Aluminum speciation studies in biological fluids. Part 7. A quantitative investigation of aluminum(III)-malate complex equilibria and their potential implications for aluminum metabolism and toxicity. J. Inorg. Biochem. 85:2001;143-154
25. Wyatt R.P., Ryde S.J.S., Morgan W.D., McNeil E.A., Hainsworth I.R., Williams A.J. The development of a technique to measure bone aluminum content using neutron activation analysis. Physiol. Meas. 14:1993;327-335